-
Uncategorized1 week ago
ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug
In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma,...
-
Uncategorized1 week agoScientists uncover a new hiding spot for HIV
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. You may have noticed a missing...
-
Uncategorized1 week ago
Regeneron deepens relationship with CytomX, adding up to $2B and eight targets
All told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met.
-
Uncategorized1 week ago
Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2
A stimulator of thyroid hormone receptors in the brain has successfully reduced depression severity in patients with bipolar disorder, positioning its maker Autobahn Therapeutics to speed...
-
Uncategorized1 week ago
Alnylam hops on AI train with up to $2B Inceptive partnership
Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies.
-
Uncategorized1 week agoDoes Revolution Medicines’ pancreatic cancer drug have even greater potential?
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Revolution Medicines’ daraxonrasib...
-
Uncategorized1 week agoWhat happens at a longevity festival?
The longevity movement is often associated with people that have enough money for a thousand lifetimes — and want to live long enough to spend it...
-
Uncategorized1 week ago
Rethinking hair loss treatment
In this episode of Denatured, you’ll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli...
-
Uncategorized1 week agoA Spanish biotech banks $87M to make differentiated ADCs
Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers. Read More
-
Uncategorized1 week ago
How long is too long? Weighing and accounting for employment gaps
It’s not unusual for it to take unemployed biopharma professionals awhile to land new jobs. Three experts discuss when employment gaps are an issue and how...
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
An obesity drug deep-dive, and peptides move mainstream
